Vérification…
Traduit automatiquement. Doses et mises en garde : vérifiez l'original en anglais. Lire en anglais
Accueil / Enregistré au Nigeria / Orphesic Tablets_

Orphesic Tablets_

NAFDAC REG NO: A4-2181 Médicament

Enregistré auprès de NAFDAC. Enregistrement actifAs of 5 November 2026 · synced automatically from official sources.
Produit
Orphesic Tablets_
Numéro NAFDAC
A4-2181
Principe actif
Orphenadrine Citrate; Paracetamol
Dosage
35 mg; 450 mg
Forme
Tablet
Conditionnement
10 x 10's (in Alu-PVC blisters)
Fabricant
Non répertorié
Déposant / Titulaire :
Laider International W.A Ltd
Approuvé
30 Jul 2025
Statut
Actif Vue sur NAFDAC ↗
Enregistrement valable jusqu'au
29 Jul 2030
Alertes OMS
Non trouvé
Community reports
None
Times checked
0

About the medicine: Paracetamol: uses, dosage and brands worldwide

What we found

  • Orphesic Tablets_ is on the NAFDAC register with an active registration (A4-2181). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Orphesic Tablets_

Ce que dit la notice officielle. Si un médecin vous l'a prescrit, suivez l'ordonnance. La notice de votre boîte prime si elle est différente.

Pour qui

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

Comment le prendre et à quelle fréquence

Adults Two tablets per day; one in the morning and one in the evening.

Children
  • Safety and effectiveness
  • In pediatric patients have not been established
Talk to a doctor first if
  • Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis
  • Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug
Warnings

Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

Effets secondaires possibles

Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. …

Pregnancy and breastfeeding

Pregnancy Pregnancy Category C Animal reproduction studies have not been conducted with orphenadrine. It is also not known whether orphenadrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Orphenadrine should be given to a pregnant woman only if clearly needed.

If you take too much

Orphenadrine is toxic when overdosed and typically induces anticholinergic effects. In a review of orphenadrine toxicity, the minimum lethal dose was found to be 2 to 3 grams for adults; however, the range of toxicity is variable and unpredictable. Treatment for orphenadrine overdose is evacuation of stomach contents (when necessary), charcoal at repeated doses, intensive monitoring, and appropriate supportive treatment of any emergent anticholinergic effects.

Dépendance et mésusage

Orphenadrine has been chronically abused for its euphoric effects. The mood elevating effects may occur at therapeutic doses of orphenadrine.

En cas d'oubli

Prenez-le dès que vous y pensez, sauf s'il est presque l'heure de la dose suivante. Dans ce cas, sautez la dose oubliée. Ne prenez jamais deux doses à la fois pour compenser. Vérifiez votre notice, certains médicaments font exception.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-01-01.

Label for orphenadrine citrate and paracetamol, the active ingredient registered with NAFDAC.

Check your pack of Orphesic Tablets_

Add the expiry date on your pack for a full Trust Score.

Ou prenez la boîte en photo
Encore 3 vérifications gratuites aujourd'hui Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Orphesic Tablets_

What is in Orphesic Tablets_?

Orphesic Tablets_ contains Orphenadrine Citrate; Paracetamol (35 mg; 450 mg), as tablet, according to its NAFDAC registration record.

Is Orphesic Tablets_ registered with NAFDAC?

Yes. Orphesic Tablets_ is listed on the NAFDAC register under registration number A4-2181, and its registration is active as of 5 November 2026.

Has Orphesic Tablets_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Orphesic Tablets_ in our automatically synced alert list.

How can I check that my pack of Orphesic Tablets_ is genuine?

Run a free authenticity scan with the NAFDAC number A4-2181, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Orphesic Tablets_?

Follow your prescription or the leaflet in your pack. The official label says: Adults Two tablets per day; one in the morning and one in the evening.…

What is Orphesic Tablets_ used for?

Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. (Summarised from the official U.S. FDA label for orphenadrine citrate and paracetamol. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Orphesic Tablets_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.